Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Overview of attention for article published in Cardiovascular Diabetology, January 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#40 of 1,464)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Dimensions has found 198 publications that cite this research output.

Article in Expert Opinion on Investigational Drugs (September 2023)

Article in ESC Heart Failure (September 2023)

Article in Diabetes Obesity and Metabolism (August 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.